US needs price controls for COVID-19 drugs, employer advocacy group says

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Dec 4, 2020 at 10:52 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,746
    Likes Received:
    3
    via The U.S. government should set prices for COVID-19 drugs and vaccines to avoid price-gouging, an advocacy group for employers told Bloomberg.

    The Employers' Prescription for Affordable Drugs said Medicare should determine fair prices for COVID-19 drugs and vaccines and pointed to Gilead's remdesivir as an example of an overpriced drug. The FDA approved remdesivir as a COVID-19 treatment in October. The drug costs private health plans more than $3,00 per treatment course, Bloomberg reported.

    article source